Background/Aims: The present study aimed to determine the changes in the epidemiology of hepatitis in recent years in an adult Turkish population.Materials and Methods: Overall, 852 patients with acute viral hepatitis from 17 centers were included in this study.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Background/Aims: The present study aimed to determine the changes in the epidemiology of hepatitis in recent years in an adult Turkish population.Materials and Methods: Overall, 852 patients with acute viral hepatitis from 17 centers were included in this study.
📊
Key Findings & Data:Their sociodemographic characteristics, clinical courses, treatments, and laboratory findings were retrospectively analyzed.Results: The most commonly found microorganisms were the hepatitis B virus (55.2%) and hepatitis A virus (37.6%), and the types of acute viral hepatitis differed significantly according to the age group (p≤0.001).
💡
Conclusion & Impact:Therefore, larger vaccination programs covering these age groups should be implemented.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Background/Aims: The present study aimed to determine the changes in the epidemiology of hepatitis in recent years in an adult Turkish population.Materials and Methods: Overall, 852 patients with acute viral hepatitis from 17 centers were included in this study. Their sociodemographic characteristics, clinical courses, treatments, and laboratory findings were retrospectively analyzed.Results: The most commonly found microorganisms were the hepatitis B virus (55.2%) and hepatitis A virus (37.6%), and the types of acute viral hepatitis differed significantly according to the age group (p≤0.001). The most frequently reported symptom was fatigue (73.7%), and the most common complications were cholecystitis (0.4%) and fulminant hepatitis (0.4%). The median hospital stay was 9 days (range 1-373). In total, 40.8% patients with acute hepatitis B virus developed immunity.Conclusion: In Turkey, there are significantly large adolescent and adult populations susceptible to acute viral hepatitis. Therefore, larger vaccination programs covering these age groups should be implemented.
🔖
Cite This Article
KARACAER, Z., TOSUN, S., BATIREL, A., ŞAHİN, S., ALTAŞ, İ., UYSAL, S., EROL, S., CERAN, N., ALBAYRAK, A., YILDIZ, İ. E., KOSTAKOĞLU, U., KAÇAR, F., KUZHAN, N., KADANALI, A., KARAGÖZ, G., YENİLMEZ, E., TURAN, D. B., YILDIRIM, A. A., KOÇAK, F., ÇETİNKAYA, R. A., ME, M. (2018). Changes in acute viral hepatitis epidemiology in the Turkish adult population: A multicenter study. Turkish Journal of Gastroenterology, Cilt: 29 - Sayı: 2, 177–182. https://ajindex.com/articles/410097
Harvala H, Wong V, Simmonds P, Johannessen I, Ramalingam S. Acute viral hepatitis - should the current screening strategy be mod-ified? J Clin Virol 2014; 59: 184-7. [CrossRef] 19. Leblebicioglu H, Eroglu C, Aribas E; Members of the Hepatitis Study Group. Acute hepatitis B virus infection in Turkey: epidemiolo-gy and genotype distribution. Clin Microbiol Infect 2004; 10: 537-41. 18. Thio CL, Hawkins C. Hepatitis B Virus and Virus, Delta. Mandell G, Bennett J, Dolin R, editors. Mandell, Dougles and Bennett’s Princi-ples and practice of Infectious Disease. 8th ed. Philadelphia: Elsevier Saunders; 2015.p.1815-39. 17. Kayaalp C, Ersan V, Yilmaz S. Acute liver failure in Turkey: a sys-tematic review. Turk J Gastroenterol 2014; 25: 35-40. [CrossRef] 16. Dayan S, Tekin A, Tekin R, et al. HBsAg, anti-HCV, anti-HIV 1/2 and syphilis seroprevalence in healthy volunteer blood donors in southeastern Anatolia. J Infect Dev Ctries 2013; 7: 665-9. [CrossRef] 15. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hep-atitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015; 21: 1020-6. [CrossRef] 14. Aydemir O, Demiray T, Koroglu M, Ciftci IH, Ozbek A, Altındis M. Hepatitis C prevalence in different age groups; people over 50 years of age may receive one-time testing for anti-HCV. Viral Hepat J 2015; 21: 40-3. [CrossRef] 13. Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 2013; 13: 181. [CrossRef] 12. Beran J, Van Der Meeren O, Leyssen M, D’silva P. Immunity to hepatitis A and B persists for at least 15 years after immunisation of adolescents with a combined hepatitis A and B vaccine. Vaccine 2016; 34: 2686-91. [CrossRef] 11. Tekin R, Yolbas I, Dal T, et al. Evaluation of adults with acute viral hepatitis a and review of the literature. Clin Ter 2013; 164: 537-41. 10. Ozden HT. Hepatitis A seroprevalence in patients with chronic viral hepatitis in Konya, Turkey. Eur J Gastroenterol Hepatol 2016; 28: 333-7. [CrossRef] 9. Alici Ö, Agalar C, Yaziciler HA. Hepatitis A seroprevalence in pa-tients who admitted to training and research hospital in Istanbul. Viral Hepat J 2013; 19: 110-4. [CrossRef] 8. Türker K, Balci E, Bati S, Hasçuhadar M, Savaş E. In our country, the changing epidemiology of hepatitis A infection. Türk Mikrobiyol Cem Derg 2011; 41: 143-8. 7. V